Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features

References

• Byrd J C, Gribben J G, Peterson B L, Grever M R, Lozanski G, Lucas D M, et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437–443
   PubMed Web of Science ®Google Scholar
• Grever M R, Lucas D M, Dewald G W, Neuberg D S, Reed J C, Kitada S, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799–804
   PubMed Web of Science ®Google Scholar
• Kay N E, Geyer S M, Call T G, Shanafelt T D, Zent C S, Jelinek D F, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B-chronic lymphocytic leukemia. Blood 2007; 109: 405–411
   PubMed Web of Science ®Google Scholar
• Bosanquet A G, McCann S R, Crotty G M, Mills M J, Catovsky D. Methylprednisolone in advanced chronic lymphocytic leukaemia: rationale for, and effectiveness of treatment suggested by DiSC assay. Acta Haematol 1995; 93: 73–79
   PubMed Web of Science ®Google Scholar
• Thornton P D, Hamblin M, Treleaven J G, Matutes E, Lakhani A K, Catovsky D. High dose methyl prednisolone in refractory chronic lymphocytic leukaemia. Leuk Lymphoma 1999; 34: 167–170
   PubMed Web of Science ®Google Scholar
• Thornton P D, Matutes E, Bosanquet A G, Lakhani A K, Grech H, Ropner J E, et al. High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities. Ann Hematol 2003; 82: 759–765
   PubMed Web of Science ®Google Scholar
• Pettitt A R, Matutes E, Oscier D. Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects. Leukemia 2006; 20: 1441–1445
   PubMed Web of Science ®Google Scholar
• Castro J E, Bole J, Prada C E, Kipps T J. Rituximab and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Blood (Suppl.) 2004; 104: 2518
   Web of Science ®Google Scholar
• Castro J E, Bole J, Prada C E, Loria O, Kipps T J. Rituximab and high dose methylprednisolone (HDMP) as a first line treatment for patients with chronic lymphocytic leukemia. Blood (Suppl.) 2005; 106: 2969
   PubMed Web of Science ®Google Scholar
• Byrd J C, Rai K, Peterson B L, Appelbaum F R, Morrison V A, Kolitz J E, et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005; 105: 49–53
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Jelinek D, Tschumper R, Schwager S, Nowakowski G, DeWald G W, Kay N E. Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 3218–3219, author reply 3219 – 3220
   PubMed Web of Science ®Google Scholar
• Shanafelt T D, Witzig T E, Fink S R, Jenkins R B, Paternoster S F, Smoley S A, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634–4641
   PubMed Web of Science ®Google Scholar
• Dewald G W, Brockman S R, Pasternoster S F, Bone N D, O'Fallon J R, Allmer C, et al. Chromosome anomalies detected by interphase fluorescent in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukemia. Br J Haematol 2003; 121: 287–295
   PubMed Web of Science ®Google Scholar
• Jelinek D F, Tschumper R C, Geyer S M, Bone N D, Dewald G W, Hanson C A, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol 2001; 115: 854–861
   PubMed Web of Science ®Google Scholar
• Jelinek D F, Tschumper R C, Stolovitzky G A, Iturria S J, Tu Y, Lepre J, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res 2003; 1: 346–361
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N E, Keating M, O'Brien O, et al. National Cancer Institute-Sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Lozanski G, Heerema N, Flinn I, Smith L, Harbison J, Webb J, et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 102: 3278–3281
   Web of Science ®Google Scholar